Business Standard

Gland Pharma's grey market premium soars ahead of Friday's debut

The retail and HNI portion of the IPO were subscribed just 51 per cent and 24 per cent, respectively

IPO
Premium

Market players said the episode underscores why investors should not entirely place their bets based on grey market activity

Sundar Sethuraman Thiruvananthapuram
Gland Pharma shares are in demand in the grey market. Ahead of its listing, the grey market premium (GMP) has soared from Rs 10 to Rs 140 a share — an indication that the stock could do well in the secondary market.

At the time of its initial public offering (IPO), however, there was hardly any demand. This discouraged many retail and high networth individuals (HNIs), who subsequently gave the IPO a miss. The retail and HNI portions were subscribed just 51 per cent and 24 per cent. The Rs 6,480-crore IPO managed to sail through solely on the back of

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in